Cargando…

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications

Alterations in protein-protein and DNA-protein interactions and abnormal chromatin remodeling are a major cause of uncontrolled gene transcription and constitutive activation of critical signaling pathways in cancer cells. Multiple epigenetic regulators are known to be deregulated in several hematol...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes-Garau, Diana, Ribeiro, Marcelo L., Roué, Gaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826405/
https://www.ncbi.nlm.nih.gov/pubmed/31581671
http://dx.doi.org/10.3390/cancers11101483
_version_ 1783465077917089792
author Reyes-Garau, Diana
Ribeiro, Marcelo L.
Roué, Gaël
author_facet Reyes-Garau, Diana
Ribeiro, Marcelo L.
Roué, Gaël
author_sort Reyes-Garau, Diana
collection PubMed
description Alterations in protein-protein and DNA-protein interactions and abnormal chromatin remodeling are a major cause of uncontrolled gene transcription and constitutive activation of critical signaling pathways in cancer cells. Multiple epigenetic regulators are known to be deregulated in several hematologic neoplasms, by somatic mutation, amplification, or deletion, allowing the identification of specific epigenetic signatures, but at the same time providing new therapeutic opportunities. While these vulnerabilities have been traditionally addressed by hypomethylating agents or histone deacetylase inhibitors, pharmacological targeting of bromodomain-containing proteins has recently emerged as a promising approach in a number of lymphoid and myeloid malignancies. Indeed, preclinical and clinical studies highlight the relevance of targeting the bromodomain and extra-terminal (BET) family as an efficient strategy of target transcription irrespective of the presence of epigenetic mutations. Here we will summarize the main advances achieved in the last decade regarding the preclinical and clinical evaluation of BET bromodomain inhibitors in hematologic cancers, either as monotherapies or in combinations with standard and/or experimental agents. A mention will finally be given to the new concept of the protein degrader, and the perspective it holds for the design of bromodomain-based therapies.
format Online
Article
Text
id pubmed-6826405
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68264052019-11-18 Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications Reyes-Garau, Diana Ribeiro, Marcelo L. Roué, Gaël Cancers (Basel) Review Alterations in protein-protein and DNA-protein interactions and abnormal chromatin remodeling are a major cause of uncontrolled gene transcription and constitutive activation of critical signaling pathways in cancer cells. Multiple epigenetic regulators are known to be deregulated in several hematologic neoplasms, by somatic mutation, amplification, or deletion, allowing the identification of specific epigenetic signatures, but at the same time providing new therapeutic opportunities. While these vulnerabilities have been traditionally addressed by hypomethylating agents or histone deacetylase inhibitors, pharmacological targeting of bromodomain-containing proteins has recently emerged as a promising approach in a number of lymphoid and myeloid malignancies. Indeed, preclinical and clinical studies highlight the relevance of targeting the bromodomain and extra-terminal (BET) family as an efficient strategy of target transcription irrespective of the presence of epigenetic mutations. Here we will summarize the main advances achieved in the last decade regarding the preclinical and clinical evaluation of BET bromodomain inhibitors in hematologic cancers, either as monotherapies or in combinations with standard and/or experimental agents. A mention will finally be given to the new concept of the protein degrader, and the perspective it holds for the design of bromodomain-based therapies. MDPI 2019-10-02 /pmc/articles/PMC6826405/ /pubmed/31581671 http://dx.doi.org/10.3390/cancers11101483 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reyes-Garau, Diana
Ribeiro, Marcelo L.
Roué, Gaël
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
title Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
title_full Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
title_fullStr Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
title_full_unstemmed Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
title_short Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
title_sort pharmacological targeting of bet bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826405/
https://www.ncbi.nlm.nih.gov/pubmed/31581671
http://dx.doi.org/10.3390/cancers11101483
work_keys_str_mv AT reyesgaraudiana pharmacologicaltargetingofbetbromodomainproteinsinacutemyeloidleukemiaandmalignantlymphomasfrommolecularcharacterizationtoclinicalapplications
AT ribeiromarcelol pharmacologicaltargetingofbetbromodomainproteinsinacutemyeloidleukemiaandmalignantlymphomasfrommolecularcharacterizationtoclinicalapplications
AT rouegael pharmacologicaltargetingofbetbromodomainproteinsinacutemyeloidleukemiaandmalignantlymphomasfrommolecularcharacterizationtoclinicalapplications